MedPath

Effects Of The Long-Term Administration Of Nebivolol On The Clinical Symptoms, Exercise Capacity And Left Ventricular Function Of The Patients With Diastolic Dysfunction (ELANDD) - ELANDD

Active, not recruiting
Conditions
Subjects with diastolic dysfunction
Registration Number
EUCTR2004-000746-20-PT
Lead Sponsor
Menarini Benelux S.A/N.V.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
180
Inclusion Criteria

1)The subject is aged =40 years
2a) Symptoms of heart failure; a documented history of heart failure
3a) A left ventricular ejection fraction = 45% assessed by echocardiography, radionuclide ventriculography or magnetic resonance (MRI)
4a) NYHA functional class II or III
6a) The subject has given written informed consent for participation in the study. The subject is able and willing to visit the hospital for the planned study visits
10) Any diastolic abnormality well documented on echocardiography following the diagnostic criteria for diastolic heart failure published by the 'European Study Group on Diastolic Heart Failure'

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. The subject is unable to perform a 6 minutes walking test
3. Planned invasive cardiac procedures carried out during the study e.g. 6 months after randomization
4. The subject had recently (< 3 months) unstable angina, acute myocardial infarction or stroke treated with a beta blocker
5. The subject has exercise induced myocardial ischemia as a main cause of exercise impairment as shown by limiting symptoms (angina) or by the previous exams (exercise test, exercise echocardiography or myocardial scintigraphy)
6. The subject has concomitant diseases (COPD, peripheral arterial disease, orthopedic diseases) as the main cause of exercise impairment
7. Presence of major contraindications to beta-blocker therapy: severe sinus bradycardia (<50 beats/min), atrio-ventricular block, bronchial asthma sensitive to beta-agonist agents
8. The subject is treated with verapamil or diltiazem
9. The subject has a systolic blood pressure < 100 mmHg
10a. The subject is pregnant, or breast feading, or of childbearing potential without using adequate contraception.
11. The subject has a history of alcohol or other illicit drug abuse
12a. The subject suffers from any other medical condition that may interfere with the objective of the study according to the investigator's judgment.
13a. The subject is expected to have a poor compliance to drug therapy.
14a. The subject is participating in any other clinical trial with an investigational product, or the subject is scheduled to recieve any such product during the study or in the 4 weeks following the study.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: This study is designed to assess the long-term effects of the administration of nebivolol, compared to placebo, on the clinical symptoms, exercise capacity and parameters of left ventricular function in the patients with diastolic heart failure.;Secondary Objective: ;Primary end point(s): The distance as recorded in the 6 minutes walking test
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath